EP 4153167 A4 20240228 - METHOD OF TREATING AML SUBTYPES USING ARGININE-DEPLETING AGENTS
Title (en)
METHOD OF TREATING AML SUBTYPES USING ARGININE-DEPLETING AGENTS
Title (de)
VERFAHREN ZUR BEHANDLUNG VON AML-SUBTYPEN MIT ARGININ-DEPLETIONSMITTELN
Title (fr)
MÉTHODE DE TRAITEMENT DE SOUS-TYPES DE LMA À L'AIDE D'AGENTS DE DÉPLÉTION DE L'ARGININE
Publication
Application
Priority
CN 2020098681 W 20200629
Abstract (en)
[origin: WO2022000151A1] A method for treating acute myeloid leukemia (AML) in a subject in need thereof, said method comprising administering a therapeutically effective amount of an arginine-depleting agent to the subject, wherein the AML is of the French-American-British (FAB) subtype M0 (undifferentiated acute myeloblastic leukemia), M2 (acute myeloblastic leukemia with maturation), M4 (acute myeloblastic leukemia with maturation), M4 eos (acute myelomonocytic leukemia with eosinophilia), M5 (acute monocytic leukemia) M6 (acute erythroid leukemia) or M7 (acute megakaryoblastic leukemia). A medicament comprising an arginine-depleting agent for the treatment of AML in a subject in need thereof, wherein the AML is of the French-American-British (FAB) subtype M0 (undifferentiated acute myeloblastic leukemia), M2 (acute myeloblastic leukemia with maturation), M4 (acute myeloblastic leukemia with maturation), M4 eos (acute myelomonocytic leukemia with eosinophilia), M5 (acute monocytic leukemia), M6 (acute erythroid leukemia) or M7 (acute megakaryoblastic leukemia).
IPC 8 full level
A61K 31/335 (2006.01); C07K 14/00 (2006.01); C07K 14/765 (2006.01)
CPC (source: EP KR)
A61K 9/0019 (2013.01 - KR); A61K 38/38 (2013.01 - KR); A61K 38/50 (2013.01 - KR); A61P 35/00 (2018.01 - EP); A61P 35/02 (2018.01 - KR); C07K 14/765 (2013.01 - EP)
Citation (search report)
- [XY] WO 2013151568 A1 20131010 - POLARIS GROUP, et al
- [Y] WO 2006015512 A1 20060216 - SHANGHAI FUDAN ZHANGJIANG BIO [CN], et al & DATABASE Geneseq [online] 15 June 2007 (2007-06-15), "Arginine deiminase.", retrieved from EBI accession no. GSP:AEF74467 Database accession no. AEF74467
- [XY] TSAI HUI-JEN ET AL: "A Phase II Study of Arginine Deiminase (ADI-PEG20) in Relapsed/Refractory or Poor-Risk Acute Myeloid Leukemia Patients", SCIENTIFIC REPORTS, vol. 7, no. 1, 12 September 2017 (2017-09-12), US, pages 1 - 10, XP055886883, ISSN: 2045-2322, Retrieved from the Internet <URL:https://www.nature.com/articles/s41598-017-10542-4.pdf> DOI: 10.1038/s41598-017-10542-4
- [Y] DATTA SAYANTAP ET AL: "Human Arginase I (Arg I)-A Potential Broad-spectrum Anti-cancer Agent: Perspectives and the Road Ahead", RESEARCH & REVIEWS: JOURNAL OF ONCOLOGY AND HEMATOLOGY, vol. 9, no. 3, 1 January 2020 (2020-01-01), pages 23 - 35, XP055972770, DOI: 10.37591/rrjooh.v9i3.2312
- [A] CHOW JEREMY P. H. ET AL: "A modified arginine-depleting enzyme NEI-01 inhibits growth of pancreatic cancer cells", PLOS ONE, vol. 15, no. 4, 30 April 2020 (2020-04-30), US, pages e0231633, XP093119859, ISSN: 1932-6203, DOI: 10.1371/journal.pone.0231633
- See also references of WO 2022000151A1
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
DOCDB simple family (publication)
WO 2022000151 A1 20220106; CA 3187578 A1 20220106; CN 115697320 A 20230203; EP 4153167 A1 20230329; EP 4153167 A4 20240228; KR 20230104110 A 20230707; TW 202206095 A 20220216
DOCDB simple family (application)
CN 2020098681 W 20200629; CA 3187578 A 20200629; CN 202080101412 A 20200629; EP 20943510 A 20200629; KR 20237003309 A 20200629; TW 110105746 A 20210219